The prognosis for patients with myelodysplastic syndrome with hypomethylating treatment failure (MDS-HTF) has been known to be poor. However, the clinical outcomes and optimal treatment options for secondary AML evolving from MDS-HTF (sAML/MDS-HTF) are not well known. This retrospective analysis was conducted to evaluate the clinical outcomes and influences of treatment options on survival in 46 consecutive patients with sAML/MDS-HTF. The median OS rates were 1.4 months in the best supportive care group (n ¼ 15) and 9.4 months in the active treatment group (n ¼ 31). One-year OS rates were 13.3% and 36.8%, respectively (P ¼ 0.001). Active treatment (Po0.001), lower BM blast (o33%) at sAML (P ¼ 0.007), non-poor NCCN (National Cancer Comprehensive Network) cytogenetics (P ¼ 0.001) and good performance status (ECOG (Eastern Cooperative Oncology Group) p1) (P ¼ 0.024) were significant predictors affecting favorable OS in a multivariate analysis. Of the active treatment options, allo-SCT with prior chemotherapy (CTx) showed better OS compared with CTx only or SCT without CTx (P ¼ 0.019). Our analyses suggest that active treatment, particularly SCT following CTx, should be considered in patients with sAML/MDS-HTF if the patient is medically fit.
INTRODUCTION
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic stem cell disorders with a dismal prognosis, particularly in patients with higher-risk MDS or lower-risk MDS with poor prognostic features. 1, 2 Among the new treatment options for patients with MDS, hypomethylating agents (HMA) such as azacitidine (AZA) and decitabine (DAC) have demonstrated improvement in cytopenia and acquisition of transfusion independency. [3] [4] [5] Furthermore, AZA alters the natural course of the disease by reducing the risk of transformation to secondary sAML as well as providing survival benefits in patients with higherrisk MDS. 6 However, 40-50% of patients do not tolerate or respond to HMA (primary hypomethylating treatment failure (HTF)), and most responders experience relapse or disease progression (secondary HTF) within 2 years of the response. 4 Recent reports have shown a poor prognosis for patients with MDS experiencing HTF (MDS-HTF). Jabbour et al. 8 reported that patients with HTF following DAC treatment had a median survival of 4.3 months. Prebet et al. 8 showed a median survival of 5.6 months and a 2-year survival probability of 15.0% in patients with HTF following AZA treatment. The authors showed that allo-SCT or investigational therapy resulted in better survival compared with conventional care in patients with MDS-HTF. The observation that higher BM blast count was a poor predictor for survival and that there was a poor response rate to intensive chemotherapy (CTx) for sAML with a prior history of HMA prompted us to investigate the role of active treatment in patients with sAML evolving from MDS-HTF (sAML/ MDS-HTF). 8, 9 None of the prior studies have analyzed the impact of SCT on the survival of patients with sAML/MDS-HTF, although one group reported a poor outcome in patients with HTF in whom AZA was administered for sAML. 10 The aim of the present study was to evaluate the influences of therapeutic modalities on the survival of patients with sAML/MDS-HTF by analyzing clinical outcomes according to the treatment option.
PATIENTS AND METHODS

Characteristics of the enrolled patients
Forty-six consecutive patients who were diagnosed with sAML/MDS-HTF between February 2005 and March 2012 at our institution were reviewed retrospectively. Prior to HMA treatment (HMT), 2 (4.3%) patients were treated with rabbit antithymocyte globulin and oxymetholone, respectively. However, no patient received any treatment between HTF and transformation to sAML except for supportive care. The median age of the patients was 57 years (range, 17-81 years) at the time of sAML/MDS-HTF diagnosis. HMA included AZA in 33 (71.7%) patients, DAC in 8 (17.4%), and AZA plus subsequent DAC, or vice versa, in 5 (10.9%). The patients received standard doses and schedules of AZA and DAC. AZA was given subcutaneously at 75 mg/m 2 per day for 7 days and DAC was administed intravenously at 20 mg/m 2 per day for 5 days every 28 days. Fifteen (32.6%) of the 46 patients experienced a response during HMT, three (6.5%) CR, one (2.2%) PR, eight (17.4%) marrow CR and three (6.5%) hematological improvement. Median BM blast count at sAML was 33.0% (range, 12.0-95.0). Thirty-two (69.6%) patients were diagnosed with HTF as sAML and the others (n ¼ 14, 30.4%) were diagnosed with sAML, median 2.5 months (range, 0.2-15.7) after HTF. Other demographics and clinical characteristics of the patients are summarized in Table 1 . This retrospective study was approved by the Institutional Review Board of Seoul St Mary's Hospital of the Catholic University of Korea.
Treatment options
Best supportive care (BSC) was considered for patients who could not tolerate intensive treatment. Active treatment options included CTx or allo-SCT and were considered for younger patients (p60 years) with good performance status (ECOG (Eastern Cooperative Oncology Group) p1). Debulking CTx prior to allo-SCT was the preferred option, but the treatment option selection after transformation to sAML was based on individual clinical circumstances and decided by the patients' preference and treating physician's discretion. Actually, immediate SCT was performed without CTx due to the patients' preference (n ¼ 2) or the donor's schedule (n ¼ 4). BSC included blood transfusions, antibiotic therapy and appropriate control of white cell counts using intermittent i.v. administration of cytarabine, hydroxyurea or leukapheresis.
CTx for sAML 
Transplantation procedures
A myeloablative conditioning regimen of FB4 (fludarabine 30 mg/m 2 for 5 days and i.v. BU 3.2 mg/kg for 4 days) was used but its intensity was reduced to FB2 plus 400 cGy TBI for those who could not tolerate the myeloablative regimen. 11 The protocol for transplant procedures except the conditioning step for the different donor sources was the same as in a previous report. 12 GVHD prophylaxis consisting of short-course MTX (5 or 10 mg/m 2 i.v. bolus on days þ 1, þ 3, þ 6 and þ 11) plus cyclosporin or tacrolimus was used for related or unrelated and alternative donor allo-SCT, respectively. Rabbit antithymocyte globulin was used with a median dose of 5 mg/kg (range, 2.5-10.0 mg/kg) for 14 (70.0%) patients with a high risk of acute GVHD, who had received allo-SCT from an unrelated or alternative donor in accordance with the protocols at our SCT center. 13 
Definitions
The diagnosis of MDS and AML was made by the World Health Organization classification 14 and the MDS risk group was classified by the International Prognostic Scoring System. 15 The assessment of response and treatment failure to HMA followed the modified International Working Group 2006 response criteria. 16 Cytogenetic risk assessment at sAML/MDS-HTF was made by the National Cancer Comprehensive Network (NCCN) guidelines. 17 Performance status and comorbidity were assessed by ECOG performance scale 18 and the hematopoietic SCT specific comorbidity index (HCT-CI), respectively. 19, 20 Acute GVHD and chronic GVHD were assessed by the National Institutes of Health (NIH) Consensus Criteria. 21 
Statistical analysis
Continuous variables are summarized as median and range. Categorical variables are described by counts and relative frequencies. Comparisons of demographics and clinical characteristics were performed using the w 2 test or Fisher's exact test for categorical variables and independent two sample t-test for continuous variables. Curves for OS were plotted using the Kaplan-Meier method and compared using the log-rank test. OS was measured from the date of diagnosis of sAML until death due to any cause, and observations ended at the date of last contact for patients last known to be alive. Patients without events were censored. The prognostic significance of the demographics and clinical factors affecting OS were determined using the Cox proportional hazard ratio (HR) model. Factors were considered significant if they had an associated P-value ofo0.05 as determined by the likelihood ratio test, using two-tailed significance testing. Statistical analyses were performed with the Statistical Package for the Social Sciences, version 13.0 (SPSS, Inc. Chicago, IL, USA) and R, version 2.15.0 (R Development Core Team, Vienna, Austria).
RESULTS
Patients and overall treatment
Fifteen patients (32.6%) received BSC and the remaining 31 (67.4%) received active treatment (Table 1) . The BSC group consisted of older patients (460 years) in comparison with the active treatment group (66.7% vs 29.0%, P ¼ 0.015), but the distribution of other characteristics including performance status and comorbidities assessed by ECOG (P ¼ 0.135) and HCT-CI (P ¼ 0.766) was similar between the two groups.
Active treatment The median time between HTF and CTx initiation was 0.8 months (range, 0.1-14.9). Twenty-five patients were given induction CTx and seven (28.0%) achieved CR. Reinduction CTx in 12 patients induced a CR in only one patient, whereas none of the three patients receiving a second round of reinduction CTx achieved a response. Following CTx, 14 patients proceeded to SCT and 7 were in CR but the remaining 7 were in a refractory or relapsed state. An additional six patients received SCT without prior CTx. The conditioning regimens for SCT were myeloablative in 11 (55.0%) and reduced intensity regimen in 9 (45.0%) patients. Fifteen (75.0%) patients received SCT from conventional (HLA-compatible sibling or unrelated) donors, four (20.0%) from haploidentical familial donors, and one (5.0%) from cord blood. The cumulative incidence at 1 year of treatment-related mortality, relapse, acute GVHD (grade X2) and chronic GVHD were 15.0% (95% confidence interval (CI), 5.1-39.6) and 51.7% (95% CI, 31.7-75.0), 45.0% (95% CI, 26.5-68.7) and 40.0% (95% CI, 22.4-64.3), respectively.
Survival benefits following active treatment
The median follow-up for survivors was 12.3 months (range, 2.9-37.7 months) and the median OS and probability of 1-year OS of all patients were 6.1 months (range, 0.1-37.7 months) and 29.2% (95% CI, 18.2-46.7), respectively. When OS was compared between patients who underwent BSC and those who received active treatment, the latter showed longer median survival (9.4 vs 1.4 months) and higher 1-year OS (36.8% vs 13.3%) compared with those in the BSC group (Figure 1a , P ¼ 0.001). BM blast count at sAML (Figure 1b , BM blastp33% 43.7% vs BM blast 433% 12.2%, P ¼ 0.007), NCCN cytogenetic risk group (Figure 1c , intermediaterisk 38.7% vs high-risk 0.0%, P ¼ 0.002), response to HMT (response to HMT 6.7% vs no response to HMT 41.9%, P ¼ 0.031) and performance status (ECOGp1 33.5% vs ECOGX2 16.7%, P ¼ 0.004) were also significant predictors for 1-year OS (Figure 1d) . However, the predictive value of higher BM blast at sAML (HR, 2.9; 95% CI, 1.3-6.2, P ¼ 0.007), poor NCCN cytogenetic risk (HR, 4.2; 95% CI, 1.7-10.2, P ¼ 0.001), BSC (HR, 6.4; 95% CI, 2.7-15.2, Po0.001) and poor performance status (HR, 2.5; 95% CI, 1.1-5.6, P ¼ 0.024) remained the only statistically significant poor predictors for OS when the multivariate analysis was performed (Table 2) .
Best survival benefits following sequential treatment with CTx and allo-SCT Further analysis in patients receiving active treatment showed that median OS in the SCT with prior CTx group (n ¼ 14), SCT without prior CTx group (n ¼ 6) and the CTx-only group (n ¼ 11) was 15.0, 3.8 and 6.3 months, respectively. The SCT with prior CTx group (1-year OS, 56.2%; 95% CI, 35.2-90.0) showed better OS when compared with the SCT without prior CTx (1-year OS, 16.7%; 95% CI, 2.8-99.7) or CTx-only groups (1-year OS, 17.7%; 95% CI, 3.4-91.9) (Figure 2a , P ¼ 0.019). Although the OS of patients receiving SCT without the achievement of CR after CTx (n ¼ 7; 1-year OS, 42.9%; 95% CI 18.2-100) was comparable to that of patients with CR (n ¼ 7; 1-year OS, 68.6%; 95% CI, 40.3-100, P ¼ 0.671), it was better when compared with the result of the patients who received immediate SCT without prior CTx (P ¼ 0.042). In a further subgroup analysis of SCT, patients with BM blasts o10% (n ¼ 9; 1-year OS, 76.2%; 95% CI, 52.1-100.0) showed higher 1-year OS in comparison with those with BM blasts X10% (n ¼ 11; 1-year OS, 18.2%; 95% CI, 5.2-63.7) and the differences were statistically significant (Figure 2b , P ¼ 0.030). Patients who received SCT from alternative donors including haploidentical donors and cord blood (1-year OS, 60.0%; 95% CI, 29.3-100) did not show inferior 1-year OS in comparison with those who received SCT from conventional donors (1-year OS, 38.9%; 95% CI, 20.3-74.4, P ¼ 0.455). All patients received prior CTx and 4 (80.0%) patients had BM blast o10% at SCT in the alternative donor SCT group, whereas 9 (60.0%) patients received prior CTx and 5 (33.3%) patients had BM blast o10% at SCT in the conventional donor group although they did not reach significant difference (P ¼ 0.129 and P ¼ 0.098, respectively).
DISCUSSION
The present study was conducted to analyze the outcomes of patients with sAML/MDS-HTF. The prognosis of these patients was poor, with a median OS of 6.1 months and a 1-year OS rate of 29.2%, which was similar to the results of previous reports (5.6 months and 28.9% after AZA failure 7 and 4.3 months and 28.0% after DAC failure 8 ). However, a smaller proportion of the patients with sAML/MDS-HTF was included in those studies, whereas all patients in this study were diagnosed with sAML/MDS-HTF. Actually, the median survival from BSC in this study was only 1.4 months, but it was 4.1 months for the AZA failure cohort, 8 suggesting the aggressiveness of the disease characteristics of our cohort. The DAC failure cohort, which included about 30% of the patients with sAML/MDS-HTF, showed a shorter median survival of 4.3 months, but no survival difference was observed between patients with sAML and MDS. 7 We thought that our treatment outcomes were relatively good when the disease status was considered, which could be due to the differences in treatment options; 20 of 46 (43.5%) patients in our cohort received allo-SCT; however, only 37 of 435 (8.5%) patients in an AZA cohort 7 and 5 of 75 (5.7%) in a DAC cohort received allo-SCT. 8 As a significantly superior median survival of 19.5 months was achieved by SCT, 8 our study also showed superior OS in patients receiving SCT. Even conventional CTx rather than BSC prolonged survival, which was significant in patients with MDS-HTF, 8 in our cohort of sAML/MDS-HTF (P ¼ 0.050, data not shown). All these observations suggest that active treatment should be considered when the patient is in a medically fit condition.
Our observation of superior survival in actively treated patients rather than in those receiving BSC could be biased by the retrospective nature of the study and the selection process of the treatment options primarily focusing on patient age and medical status. Although performance and comorbidities were not different between the two groups, patients in the active treatment group were younger in comparison with those in the BSC group, suggesting that active treatment, particularly for SCT, was chosen by age in our routine practice. However, the statistical analysis showed that age did not affect OS, although it was limited by the small number of cases. We thought that selecting CTx followed by SCT with a consideration of the cytogenetic risk group, rather than being limited by age, could be helpful in prolonging survival in these patients. In line with our observation, recent data have shown that older age alone should not be considered a contraindication to SCT in medically fit patients. 22, 23 Alternative donors for SCT such as a haploidentical familial member can be a feasible option if a HLA-compatible donor is unavailable, as most patients with sAML/MDS-HTF die within 6 months without allo-SCT and the median CR duration after CTx was within 3.6 months. 9 The 1-year OS of 60.0% in our cohort suggested the feasibility of alternative donor SCT as an alternative option for these high-risk patients.
Response to CTx in sAML transformed from MDS was 32.0% when the patients had a history of HMT or lenalidomide. 9 A similar low CR rate (28.0%) was also observed in the first cycle of induction CTx and CTx-only showed minimal benefits compared to BSC in this study. The reason for the negative impact on the outcomes induced by prior HMT for MDS in patients with sAML is unclear. One hypothesis invokes the upregulation of the multidrug resistance 1 gene activated through the demethylation of its promoter by HMA. 24 The multidrug resistance 1 gene is a major cause of CTx resistance in patients with AML. 25 Although the role of induction CTx prior to allo-SCT remains undetermined, 26 our cohort showed that pretransplant CTx induced better transplant outcomes, particularly when BM blasts were downregulated to o10%. Whereas the OS of patients receiving SCT without achievement of CR after CTx was comparable with that of patients with CR, it was better in comparison with the results in those who received immediate SCT without prior CTx. This suggests that while debulking is necessary, acquisition of CR is not an obligate endpoint of pretransplant CTx in sAML/MDS-HTF. CTx may serve as a cytoreductive treatment, but its other roles, such as in the elimination of HMA-resistant clones, should be considered. Novel nucleoside analogs such as clofarabine and sapacitabine have been extensively studied in patients with MDS, and their response rates are 30-40%. Both drugs are also being targeted in patients who failed to respond to prior HMT.
27-29
The results of our study suggest that patients with sAML/MDS-HTF may be better served by active treatment, particularly with CTx followed by allo-SCT rather than with BSC if their performance status and comorbidities permit. Although this study was carried out in consecutive patients in a single center, it has the inherent limitations of a retrospective nature and a relatively small number of patients, and bias was also involved in the selection of treatment options. Future studies to analyze the potential role of active treatment using CTx and SCT should be planned to validate our suggestions and may reveal the optimal candidates for the therapeutic approaches.
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